Amarin (NASDAQ:AMRN) Releases Earnings Results, Beats Estimates By $0.02 EPS

Amarin (NASDAQ:AMRN) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02, Yahoo Finance reports. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. The business had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. During the same quarter last year, the business posted ($0.04) earnings per share.

Amarin Trading Up 9.4 %

Shares of AMRN stock traded up $0.08 on Thursday, reaching $0.92. The company had a trading volume of 1,479,096 shares, compared to its average volume of 1,940,914. The company has a 50-day moving average of $0.95 and a 200-day moving average of $0.94. Amarin has a 12 month low of $0.65 and a 12 month high of $1.49. The stock has a market cap of $377.00 million, a PE ratio of -6.39 and a beta of 1.95.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.